All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Not difficult at all
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with myelofibrosis (MF)?
How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?
In this video, Mascarenhas discusses the analysis from the PERSIST-2 trial (NCT02055781), a randomized phase III study that investigated the safety and efficacy of oral pacritinib compared to the best available therapy to treat MF with thrombocytopenia.
Editorial theme | The management of relapsed/refractory myelofibrosis: Part 2 – novel JAK inhibitors
As part of the new editorial theme on the management of relapsed or refractory myelofibrosis (R/R MF), we are now looking at the emerging therapeutic...
Reviewing the safety of JAK inhibitors for the treatment of myelofibrosis
Over the past decade, seminal studies have led to the identification of specific driver mutations in the pathogenesis of myelofibrosis (MF) and related myeloproliferative...
Subscribe to get the best content related to MPN delivered to your inbox